Novel approaches to lipid lowering: What is on the horizon?

American Journal of Cardiology

Volumn 87, Issue 5 SUPPL. 1, 2001, Pages 23-27

  Brown, W Virgil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AVASIMIBE; CERIVASTATIN; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTERY LESION; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG APPROVAL; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MACROPHAGE; PRIORITY JOURNAL;

EID: 0035825939     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01452-7     Document Type: Conference Paper

References (21)

1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
7. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia
8. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients
9. Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin
10. Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia
11. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
12. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
13. Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
14. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress
15. Triglyceride as a risk factor for coronary artery disease
16. +/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits
17. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
18. Inhibitory effect of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters
19. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH 58235: Pooled analysis of two phase II studies [abstract]
20. A target for cholesterol absorption inhibitors in the enterocyte brush border membrane
21. Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter